Navigation Links
Compendia Bioscience Releases Oncomine Concepts Edition 4.0
Date:3/26/2009

With User Inspired Features and a Redesigned Interface, Oncomine Remains Data-Focused

ANN ARBOR, Mich., March 26 /PRNewswire-USNewswire/ -- Compendia Bioscience announces the release of Oncomine Concepts Edition version 4.0, the latest incarnation of the company's flagship product. Since its inception at the University of Michigan, Oncomine has been rapidly adopted by drug discovery and development organizations looking to improve results of cancer drug development efforts. This new version of Oncomine features an improved user-interface and new export function that allows results sharing.

Cancer researchers and drug developers have made Oncomine the industry-standard, with 15 of the top 20 cancer research companies using this product for interactive access and in-depth analysis of curated cancer genomics data. Oncomine has led to several major cancer research discoveries such as the presence of gene fusions in the majority of prostate cancers (Cancer Cell, Volume 13 Issue 6: June 2008. Nature, Aug 2 2007).

"In accumulating so much high-value data, our biggest success has created our biggest challenge," commented Compendia CEO and Co-founder Dan Rhodes, Ph.D. "It has become difficult to navigate all of the data and analyses to answer the burning questions at hand. Oncomine Concepts Edition 4.0 makes these efforts more intuitive and much, much easier."

New Functionality in Oncomine Concepts Edition 4.0

  • Implementation of the Compendia Ontology - a multi-threaded tree of terms that facilitates searching and browsing data
  • Smart search - the ability to include as many genes as desired in a search request as well as an auto-complete feature using terms from the Compendia Ontology
  • Unified user interface - the ability to view the list of results and individual visualizations within a single browser window
  • Seamless integration of Oncomine Concepts Map - linking drugs, tumor types and biology to sets of genes without leaving the main interface
  • Bookmarks - the ability to save specific searches, results sets or analyses for later review or to share with other Oncomine users
  • Export - the ability to rapidly export results and visualizations to Excel and PowerPoint for further analysis or to share with colleagues

While improved user experience was the driving force in Oncomine Concepts Edition 4.0, the entire Oncomine database was also scrutinized in an effort to standardize and catalog all data points. Oncomine Research Edition 4.0 will be released in the later part of 2009.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com

About Oncomine(TM)

Oncomine combines a rapidly growing compendium of 30,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm

    For additional information regarding this announcement, please contact:
    John Freshley
    Chief Business Officer
    Compendia Bioscience
    Phone: (734) 945-6344
    E-mail: media@compendiabio.com


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Professionals in bioscience, food-related industries turn to K-State
4. Aeon Bioscience Continues Development of Drug Eluting Stents
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
7. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
8. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
9. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip meals occasionally (which is ... was among the many new lifestyle diet tips offered by nutritionists Pam Bonney and ... of Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, ...
(Date:4/29/2016)... FL (PRWEB) , ... April 29, 2016 , ... ... will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter ... a century of churning cream into butter, Grassland Dairy Products, located in Greenwood, ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
(Date:4/27/2016)... 27, 2016 At the Sachs ... of a Phase 2 clinical study of its lead ... undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, ... Germany and France ... at the time of surgery. "Despite advances in cochlear ...
Breaking Medicine Technology: